
BeiGene Ltd (ONC) Stock Forecast & Price Target
BeiGene Ltd (ONC) Analyst Ratings
Bulls say
BeOne Medicines is a key player in the competitive landscape of biotech firms producing oncology therapeutics. With Brukinsa, their leading product generating a majority of their revenue, BeOne is expected to continue on a solid growth trajectory. However, there are potential risks and challenges, such as intellectual property and management execution, that the company will need to navigate as they pursue other treatments for various types of cancers.
Bears say
BeOne Medicines is led by Brukinsa (zanubrutinib), with global leadership in treating CLL that has a projected peak revenue of $6.8B by 2030. However, the company's other approved drugs generate most of their revenue from China, making them less competitive on a global scale. Issues with green manufacturing processes, clinical trial conduct, diversity, and socially responsible pricing could also pose challenges, despite strong financial results in 1Q exceeding estimates.
This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.
BeiGene Ltd (ONC) Analyst Forecast & Price Prediction
Start investing in BeiGene Ltd (ONC)
Order type
Buy in
Order amount
Est. shares
0 shares